GSK Amends its Development and Commercialization Agreement with Liquidia for Inhaled Therapies

 GSK Amends its Development and Commercialization Agreement with Liquidia for Inhaled Therapies

GSK Amends its Development and Commercialization Agreement with Liquidia for Inhaled Therapies

Shots:

  • GSK to get rights to develop and commercialize three additional inhaled therapies utilizing Liquidia’s PRINT technology and can acquire rights to pursue additional PRINT based inhalation therapies. Liquidia to receives milestones & royalties with the initiation of P-III studies
  • In 2012, Liquidia & GSK collaborated to develop vaccines & inhaled therapies. Later in 2015, GSK exercised its option to license inhaled therapies developed utilizing PRINT technology except for LIQ861
  • LIQ861 (treprostinil) is a dry powder formulation based on PRINT technology, being evaluated in P-III INSPIRE study for the treatment of pulmonary arterial hypertension with its expected NDA submission in 2019

Click here to read full press release/ article | Ref: Globe NewsWire | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post